Recent Updates
Recently added Catalysts

Rilpivirine

Phase 3

HIV-1 Infection | Small molecule | Infectious Disease |Johnson & Johnson|Last Updated: Mar 4, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment482
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01266902A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1PHASE3 COMPLETED 482Feb 1, 2011Feb 1, 2020Mar 4, 202198 United States, Argentina +19
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Adverse Events (AEs)
Up to 7 years

An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.

Number of Participants With Grade 3/4 Events of Rash Irrespective of Causality
Up to 7 years

Number of participants with grade 3/4 events of rash irrespective of causality were assessed. A grade 3 rash defined as diffuse macular, maculopapular or morbilliform rash with vesicles or limited number of bullae or; rash with superficial ulcerations of mucous membranes limited to 1 anatomical site or; rash with at least one of the following: elevations in aspartate aminotransferase (AST)/alanine aminotransferase (ALT) more than 2\*baseline value and at least 5 times upper limit of normal; fever greater than (\>) 38 degree celsius or 100 degree fahrenheit; eosinophils \> 1000/millimeter (mm)\^3; serum sickness-like reaction. A grade 4 rash defined as the following: extensive or generalized bullous lesions or; Stevens-Johnsons Syndrome (SJS) or ulceration of mucous membrane involving 2 or more distinct mucosal sites or toxic epidermal necrolysis.

Secondary Endpoints
Time to Virologic Rebound
Up to Week 360
Time To Treatment Failure
Up to Week 360
Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Observed Case Approach Until Week 336
Baseline up to weeks 96, 192, 288, 336
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
RilpivirineEXPERIMENTALRilpivirine 25 mg once daily
Interventions
NameTypeDescription
RilpivirineDRUG25 mg once daily
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites98

Inclusion Criteria: * Patients are HIV-1 infected and were previously randomized to receive TMC278 in a TMC278 clinical trial and completed the protocol-defined treatment period. * Patients continue to benefit from treatment with TMC278 in the opinion of the investigator. * Patient can comply with ...

Countries:United StatesArgentinaAustraliaAustriaBelgiumCanadaChileChinaDenmarkFranceGermanyNetherlandsPuerto RicoRomaniaRussiaSouth AfricaSpainSwedenTaiwanThailandUnited Kingdom
Unlock Eligibility Criteria